In the latest close session, Pfizer (PFE) was up +1.63% at $25.56. This move outpaced the S&P 500's daily loss of 0.53%. On ...

Shares of Pfizer Inc. PFE rallied 1.71% to $25.58 Wednesday, on what proved to be an all-around poor trading session for the ...

Pfizer PFE stock has declined almost 5% in a month, losing $7.3 billion in market capitalization. Shares dipped recently ...

Despite additional cost savings in 2026, Pfizer also forecasts that its adjusted earnings per share (EPS) will likely decline ...

Every investor in Pfizer Inc. (NYSE:PFE) should be aware of the most powerful shareholder groups. With 66% stake, ...

Pfizer is a Buy at low valuation but faces a 2030 patent cliff, COVID sales declines, and LOE risks. Click here to read an ...

In the latest close session, Pfizer (PFE) was up +1.12% at $25.18. The stock outpaced the S&P 500's daily gain of 0.19%. Meanwhile, the Dow experienced a rise of 0.66%, and the technology-dominated ...

Pfizer recently announced its guidance for 2026. One thing seems clear: Its financial results won't get much stronger. It ...

Pfizer Inc. (PFE), headquartered in New York, discovers, develops, manufactures, markets, distributes, and sells ...

Pfizer's 2026 revenue midpoint of $61B and EPS midpoint of $2.90 decline YoY, reflecting persisting headwinds. Read more on ...

Pfizer is buying out Metsera for up to $10 billion after an acquisition battle with another pharma giant. Metsera's leading candidate could be an excellent way for Pfizer to enter the weight-loss drug ...